Core Viewpoint - 基石药业-B (02616.HK) announced the granting of stock options and restricted share units to employees as part of its employee stock ownership plan and restricted share award plan following its initial public offering [1] Group 1 - The company granted a total of 4.8 million stock options to 5 option grantees, with an exercise price of HKD 10.00 per share [1] - Additionally, the company awarded a total of 1.93 million restricted share units to 5 restricted share unit grantees [1]

Group 1 - The company, Basestone Pharmaceuticals-B (02616), announced the grant of a total of 4.8 million stock options to 5 option grantees for the subscription of 4.8 million shares as part of its employee shareholding plan post-initial public offering [1] - Additionally, the company granted a total of 1.93 million restricted share units to 5 restricted share unit grantees under its post-initial public offering restricted share award plan, subject to acceptance by the grantees [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CStone Pharmaceuticals 基石藥業 （於開曼群島註冊成立的有限公司） （股份代號：2616） 本公告乃根據上市規則第17.06A、17.06B及17.06C條刊發。董事會謹此宣佈， 於二零二五年八月二十七日，本公司已(i)根據首次公開發售後僱員持股計劃向5 名購股權承授人授出合共4,800,000份購股權以認購合共4,800,000股股份；及(ii) 根據首次公開發售後受限制股份獎勵計劃向5名受限制股份單位承授人授出合共 1,930,000份受限制股份單位，惟須經承授人接納作實。 I. 根據首次公開發售後僱員持股計劃授出購股權 於二零二五年八月二十七日，本公司根據首次公開發售後僱員持股計劃向5名 購股權承授人授予合共4,800,000份購股權以認購合共4,800,000股股份。 上述授出的概要載列如下： 授出日期： 二零二五年八月二十七日 購股權承授人數量： 5名（即1名董事及4名本 ...

Group 1 - The biotechnology sector in the Hong Kong stock market experienced a significant decline, with several companies reporting substantial drops in their stock prices [1] - Notable declines include Clover Biopharmaceuticals, which fell by 14.13%, and Beigene, which dropped by 8.33% [2] - Other companies such as Innovent Biologics and WuXi Biologics also saw declines exceeding 5%, indicating a broader trend of negative performance in the sector [1][2] Group 2 - The following companies reported specific percentage declines: Clover Biopharmaceuticals (-14.13%), Beigene (-8.33%), and Innovent Biologics (-6.50%) [2] - Additional companies with notable declines include Kintor Pharmaceutical (-6.38%), CanSino Biologics (-5.98%), and Zai Lab (-5.50%) [2] - The overall trend suggests a challenging environment for biotechnology stocks in the Hong Kong market [1]

Summary of Key Points Core Viewpoint - As of August 26, a total of 135 stocks reached their 52-week highs, indicating a strong market performance with notable leaders in the sector [1]. Stock Performance Highlights - The top three stocks with the highest increase rates are: - 恒基发展 (Hengji Development) at 69.72% with a closing price of 0.335 and a peak of 0.370 [1] - 中国智能交通 (China Intelligent Transportation) at 68.89% with a closing price of 0.305 and a peak of 0.380 [1] - 桦欣控股 (Hua Xin Holdings) at 54.26% with a closing price of 17.000, reaching its peak at the same price [1] Additional Notable Stocks - Other significant performers include: - 绿色经济 (Green Economy) at 22.16% [1] - 米兰站 (Milan Station) at 21.83% [1] - 永义国际 (Yongyi International) at 21.21% [1] - 金界控股 (Golden Realm Holdings) at 18.11% [1] 52-Week Low Rankings - The stocks that reached their 52-week lows include: - 鸿盛昌资源股权 (Hongsheng Chang Resources) at a low of 0.010, down 37.50% [4] - 德商产投服务 (DeShang Investment Services) at a low of 0.830, down 17.00% [4] - 新华联合投资 (Xinhua United Investment) at a low of 0.092, down 15.60% [4]

智通财经APP获悉，基石药业-B(02616)再涨超5%，截至发稿，涨4.8%，报10.7港元，成交额3.01亿港 元。 值得注意的是，公司战略合作持续落地。西南证券指出，舒格利单抗于2025年3月向欧洲药品管理局 （EMA）递交新适应症申请，用于治疗不可切除的、Ⅲ期NSCLC、同步或序贯放化疗后未出现疾病进 展的患者。2025年1月，公司与SteinCares就10个拉丁美洲国家达成商业化战略合作，于2025年7月与 Gentili就西欧23个国家及英国达成战略合作。目前，舒格利单抗的国际影响力已拓展至全球60多个国 家。 消息面上，根据香港联交所8月20日披露的文件，8月18日，新加坡政府投资公司(GIC)增持基石药业 8,040万股普通股股份，每股均价7.9港元，价值约6.35亿港元。增持后，新加坡政府投资公司最新持仓 比例由0.00%升至5.49%。 ...

Group 1 - The stock of Basilea Pharmaceutica (02616) has increased by over 5%, currently trading at 10.7 HKD with a transaction volume of 301 million HKD [1] - The Government of Singapore Investment Corporation (GIC) has increased its stake in Basilea by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD, raising its ownership from 0.00% to 5.49% [1] - The company continues to implement strategic collaborations, with Shugli monoclonal antibody expected to submit a new indication application to the European Medicines Agency (EMA) by March 2025 for treating unresectable stage III NSCLC patients [1] Group 2 - In January 2025, the company reached a commercialization strategic cooperation agreement with SteinCares for 10 Latin American countries, and in July 2025, it established a strategic partnership with Gentili for 23 countries in Western Europe and the UK [1] - The international influence of Shugli monoclonal antibody has expanded to over 60 countries globally [1]

Core Viewpoint - The stock of Basestone Pharmaceuticals (02616) has seen a significant increase, with a rise of over 9%, currently trading at 10.35 HKD, with a transaction volume of 201 million HKD. This surge follows the announcement of a substantial share acquisition by the Government of Singapore Investment Corporation (GIC) [1] Group 1: Share Acquisition - On August 18, GIC Private Limited increased its stake in Basestone Pharmaceuticals by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD. This acquisition raised GIC's ownership from 0.00% to 5.49% [1] Group 2: Clinical Trials and Product Pipeline - Guotou Securities reported that Basestone's core product, the second-generation IO product CS2009, is currently undergoing global multi-center Phase I/II clinical trials in Australia and China, with plans to expand to the U.S. for Phase II enrollment. The company expects to exceed 100 patients by the end of the year [1] - The company plans to present data from the Phase I clinical study, including safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity, at the ESMO conference in October 2025, which is highly anticipated [1] - Given the potential for product volume growth and a rich clinical development pipeline, the future development prospects for the company appear promising [1]

Core Viewpoint - The stock of Basilea Pharmaceutica (02616) has seen a significant increase, with a rise of over 9% and a current price of 10.35 HKD, driven by recent investment activities and positive clinical trial developments [1] Group 1: Investment Activity - Singapore's Government Investment Corporation (GIC Private Limited) has increased its stake in Basilea Pharmaceutica by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD [1] - Following this acquisition, GIC's ownership in Basilea has risen from 0.00% to 5.49% [1] Group 2: Clinical Development - Basilea's core product, the second-generation IO product CS2009, is currently undergoing global multi-center Phase I/II clinical trials in Australia and China, with plans to expand to the U.S. for Phase II enrollment [1] - The company anticipates that the number of patients enrolled will exceed 100 by the end of the year, with plans to initiate Phase Ib/II dose expansion and registration studies in the second half of 2025 [1] - Data from the Phase I clinical study, including safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity, is expected to be presented at the ESMO conference in October 2025, generating significant interest [1] Group 3: Future Outlook - Given the potential for product launches and a robust clinical development pipeline, the future growth prospects for Basilea are considered promising [1]

Core Viewpoint - 基石药业-B's stock price increased by 5.15% following a significant share purchase by GIC Private Limited, despite a substantial decline in revenue and ongoing losses [1] Group 1: Shareholder Activity - GIC Private Limited acquired 80.4 million shares of 基石药业 at an average price of 7.9 HKD per share, totaling approximately 635 million HKD [1] - Following this acquisition, GIC's ownership stake in 基石药业 rose from 0.00% to 5.49% [1] Group 2: Financial Performance - 基石药业 reported a revenue of 49.45 million RMB, representing a year-on-year decrease of 80.54% [1] - The company's R&D expenses increased by 58.75% to 105 million RMB [1] - The net loss for the period was 270 million RMB [1] Group 3: Strategic Outlook - The company is adjusting the pricing of its drug 普拉替尼 in preparation for negotiations regarding the national medical insurance drug list [1] - If included in the national medical insurance list, sales growth from 普拉替尼 is expected to offset short-term negative impacts on revenue starting in 2026 [1] - In the first half of 2025, the company did not enter into any significant external licensing agreements, but it signed a major external licensing agreement with Gentili in July 2025, anticipating revenue from licensing fees in the second half of 2025 [1]